Ajoeno

Ajoene: A Comprehensive Reference

1. Identity, Chemical Characterization, and Natural Source

Nomenclature and Chemical Identity

Ajoene is an organosulfur compound found in garlic (Allium sativum) extracts. Its name comes from ajo, the Spanish word for garlic, and is therefore pronounced a-ho-ene. The compound is known by two closely related systematic chemical names in the scientific literature: the IUPAC name [(E)-1-(prop-2-enyldisulfanyl)-3-prop-2-enylsulfinylprop-1-ene] and the more widely cited designation (E,Z)-4,5,9-trithiadodeca-1,6,11-triene 9-oxide. The molecular weight of ajoene is 234.4 g/mol.

Physical Characteristics and Isomers

Ajoene is a colorless liquid that contains sulfoxide and disulfide functional groups. It is an unsaturated organosulfur compound found in small quantities (0.1%–0.5%) in garlic. The natural product is a mixture of E- and Z-stereoisomers in a ratio of approximately 1:2. Commercial products typically have an E/Z ratio of approximately 2, with a range of 0.6–2.5. The E/Z ratio and yield depend on the polarity of the solvent system, reaction conditions, and the type of fatty acids present during processing. The Z-isomer is known to have stronger bioactivity compared to E-ajoene, while the E-isomer is more stable than the Z-isomer during storage.

Structure–activity studies on ajoene and ajoene analogues have revealed that the Z-isomer is moderately more active than the E-isomer at inhibiting in vitro tumor cell growth, suggesting that specific protein interactions may be important.

Natural Source and Biosynthetic Origin

Ajoene is a sulfur-rich compound derived from the enzymatic transformation of allicin in crushed garlic (Allium sativum). The biosynthetic cascade begins in the intact garlic clove: an intact garlic clove does not contain allicin but rather its odorless precursor alliin [(+)(S-allyl-L-cysteine sulfoxide)]. This is converted to allicin by a C–S-lyase present in the garlic plant termed alliinase. Alliin and alliinase are found in different compartments of the garlic clove, and cutting or crushing the clove releases the enzyme, allowing it to come into contact with alliin, which is then converted to allicin. Ajoene is then formed during the further degradation of allicin, which is a chemically unstable, colorless to straw-colored oil thought to be responsible for much of the odor and biological activity of garlic. Unlike its unstable precursor allicin, ajoene exhibits greater stability and a broad spectrum of biological activities.

Ajoene is one of the main compounds formed from heating crushed garlic as a mixture of E- and Z-isomers. It is a garlic stable, oil-soluble, sulfur-rich compound generally isolated as a mixture of two isomers. Ajoene is stable in water and can also be obtained by chemical synthesis.

Forms and Preparations

Ajoene is not a constituent of the intact garlic clove; it arises only upon processing. It is found predominantly in oil-macerates and solvent extracts of garlic prepared under elevated temperature. Research-grade ajoene is isolated from alcoholic extracts of garlic or produced by total chemical synthesis. A described five-step synthetic procedure begins with an alkyl dibromide and proceeds through selenium-containing intermediates until the selenium moiety is oxidatively cleaved with hydrogen peroxide to produce ajoene, with a thioether group converted to sulfoxide in the same step; this procedure has been scaled to produce the compound in quantities exceeding 100 g. Topical cream formulations at concentrations ranging from 0.4% to 1% have been used in published clinical studies. No standardized oral dosage form for ajoene is commercially marketed as of the current literature; preparations studied in humans have been topical.

---

2. Traditional and Historical Use

Garlic in Ancient Cultures

Ajoene as an isolated chemical entity was not known until the 1980s; its existence within garlic, however, is inseparable from garlic's several-thousand-year medicinal history. Garlic (Allium sativum), a member of the Amaryllidaceae family, has been widely utilized across traditional medical systems, including Ayurveda, Traditional Chinese Medicine, and ancient Egyptian practices, for the management of infections, respiratory disorders, and cardiovascular ailments.

Interest in the potential benefits of garlic was noted in records found in Egyptian pyramids and ancient Greek temples, as well as in ancient texts—including medical literature—from China, Egypt, Greece, India, Israel, and Rome, in which its use was prescribed. The reputation of garlic (Allium sativum) as an effective remedy for tumors extends back to the Egyptian Codex Ebers of 1550 BC.

In ancient Indian medicine, garlic was a valuable remedy used as a tonic to treat a lack of appetite, common weakness, cough, skin disease, rheumatism, and hemorrhoids. In the Vedas—the Indian holy book—garlic was mentioned among other medicinal plants. Ayurveda and Traditional Chinese Medicine emphasized the digestive and detoxifying effects of garlic, using it to balance bodily humors and eliminate intestinal parasites.

Ancient Egyptian and Roman sources describe garlic as a natural remedy for strength and endurance. Pyramid workers consumed it to boost stamina, while Roman soldiers used it to recover from physical exertion and wounds.

Connection Between Traditional Use and Modern Understanding of Ajoene

While ajoene itself was not known in ancient times—its identification and structural analysis occurred in the 1980s—its source, garlic, has an extensive historical legacy in herbal medicine. Garlic has been used for over 5,000 years across various cultures for its antimicrobial, cardiovascular, and immune-boosting properties. Early herbalists understood that crushed or aged garlic had stronger effects, likely due to the natural chemical transformations that occur upon processing—transformations now understood to include the conversion of allicin into ajoene. The curative properties of garlic in medicine have been known for a long time, but it was only in the last three decades that garlic properties were seriously investigated, confirming its potential as a therapeutic agent.

---

3. Key Constituents, Active Compounds, and Mechanisms of Action

Ajoene in the Context of Garlic's Organosulfur Chemistry

Allicin, ajoene, thiosulfinates, and a wide range of other organosulfur compounds are the constituents linked to garlic's medicinal properties. Ajoene is the garlic compound related to the greatest number of biological activities, as demonstrated in in vitro and in vivo systems. These studies found that ajoene has antithrombotic, anti-tumoral, antifungal, and antiparasitic effects.

Antiplatelet and Antithrombotic Mechanisms

Ajoene is a well-established antiplatelet agent, and its inhibitory effect on platelet aggregation has been extensively studied and documented both by in vivo and in vitro experiments. The compound acts via a mechanism distinct from other known antiplatelet drugs: in vitro, ajoene reversibly inhibits platelet aggregation as well as the release reaction induced by all known agonists, and it has a unique locus of action not shared by any other known antiplatelet compound. Specifically, ajoene inhibits agonist-induced exposure of fibrinogen receptors, as well as intracellular responses such as activation of protein kinase C and the increase in cytoplasmic free calcium induced by receptor-dependent agonists (collagen, ADP, PAF, and low-dose thrombin).

A membrane-level effect has also been characterized. Electron spin resonance studies of the effect of ajoene on physicochemical properties of the platelet plasma membrane indicated that ajoene increased the mobility of a fatty acid spin label, suggesting decreased microviscosity of the most internal region within the lipid bilayer membrane without affecting the outer hydrophilic moieties. This suggests that the effect of ajoene on the release reaction is, in part, due to physical modification of the bilayer, impairing the fusion of granules and the plasma membrane, a prerequisite for exocytosis.

For collagen-induced platelet aggregation in human platelet-rich plasma (PRP), the ID50 for ajoene is 95 ± 5 µM. Dipyridamole, which in PRP has very little effect on the dose–response curve for ajoene, when assayed in whole blood decreases the ID50 for ajoene by a factor of four, demonstrating that the antithrombotic potential of ajoene is substantially increased in the presence of physiologically and pharmacologically active antiplatelet agents.

Anticancer Mechanisms

Ajoene possesses a broad spectrum of biological activities that include anticancer activity. Its cytotoxicity toward cancer cells is postulated to occur via an apoptotic mechanism involving activation of the mitochondrial-dependent caspase cascade.

In leukemia cell models, the apoptotic pathway has been characterized in molecular detail: ajoene induced the release of cytochrome c (which was not inhibited by the broad-range caspase inhibitor zVAD-fmk, indicating that cytochrome c release precedes caspase activation), led to a dissipation of the mitochondrial transmembrane potential, and overexpression of Bcl-x(L) clearly diminished ajoene-induced caspase activation as well as apoptosis. These results indicate that apoptosis in leukemia cells triggered by ajoene is based on the activation of a mitochondria-dependent caspase cascade which includes also the activation of the initiator caspase-8.

Ajoene induced apoptosis in human leukemic cells via stimulation of peroxide production and activation of caspase-3-like and caspase-8 activity. In addition, studies have shown the antiproliferative activity of ajoene to be associated with a block in the G2/M phase of the cell cycle in human myeloid leukemia cells.

Regarding the microtubule cytoskeleton as a target: in PtK2 cells, exposure to 20 µM Z-ajoene for 6 hours induced a complete disassembly of the microtubule network, associated with an increased number of cells blocked in early mitotic stages. In vitro, a reversible inhibition of microtubule protein assembly was observed with an IC50 of 25 µM Z-ajoene. The microtubule cytoskeleton appears to be one of the Z-ajoene targets, but the mechanisms by which Z-ajoene interacted with microtubules appeared different from those of other microtubule poisons such as those of the Vinca alkaloid family.

Cholesterol and Mevalonate Pathway Inhibition

Ajoene is a garlic compound with anti-platelet properties and was shown to inhibit cholesterol biosynthesis by affecting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and late enzymatic steps of the mevalonate (MVA) pathway. MVA constitutes the precursor not only of cholesterol but also of a number of non-sterol isoprenoids such as farnesyl and geranylgeranyl groups. Covalent attachment of these MVA-derived isoprenoid groups (prenylation) is a required function of several proteins that regulate cell proliferation.

Antifungal Mechanism

Ajoene has been shown to have activity against the human dermatophyte Trichophyton rubrum, the most common cause of tinea pedis (athlete's foot). The specific mechanism of action is unclear, but is thought to be related to the inhibition of phosphatidylcholine biosynthesis in human dermatophytes.

Antiparasitic Mechanism

Ajoene, the major bioactive compound derived from garlic, shows potent trypanolytic and antimicotic activity. In parasitology, the compound's activity against Trypanosoma cruzi has been linked to its action as an inhibitor of trypanothione reductase, an enzyme critical to the parasite's antioxidant defense system.

---

4. Scientific Evidence by Area of Use

4.1 Platelet Aggregation and Cardiovascular Effects

The antiplatelet properties of ajoene are among the most extensively studied of its biological activities, though evidence remains primarily from in vitro and animal models rather than clinical trials in humans.

In vitro studies have demonstrated reversible inhibition of platelet aggregation induced by all known agonists in human platelet-rich plasma. Ajoene is a potent antiplatelet compound isolated from alcoholic extracts of garlic and reversibly inhibits in vitro platelet aggregation as well as the release reaction induced by all known agonists. Studies using a cylindrical perfusion chamber to model the effect of ajoene on platelet deposition on physiological substrates such as pig aortic subendothelium showed that ajoene prevents thrombus formation both at low and high shear rate in citrated whole blood, replicating conditions in both small and medium-sized arteries. These results suggest that ajoene may be useful for the acute prevention of thrombus formation induced by vascular damage.

In vivo animal studies documented reversible prevention of platelet activation in dogs under extracorporeal circulation. Its inhibitory effect on platelet aggregation has been extensively studied and documented both by in vivo and in vitro experiments.

Evidence strength: The antiplatelet evidence for ajoene is robust at the mechanistic level and is supported by multiple in vitro studies and animal models. There are, however, no large randomized controlled clinical trials in humans specifically evaluating ajoene as an antithrombotic agent. Several clinical trials and in vitro studies of ajoene have demonstrated its best-known anti-thrombosis, anti-microbial, and cholesterol-lowering activities, though these trials are small and not sufficient to support clinical recommendations.

4.2 Antifungal Activity — Tinea Pedis (Athlete's Foot)

Antifungal applications of ajoene represent the area with the strongest human clinical evidence. Two randomized clinical trials, both conducted by Ledezma and colleagues in Venezuela, provide controlled data.

Trial 1 (Ledezma et al., 1996 — Mycoses): This study reported the efficacy of ajoene, a garlic-derived organic trisulfur, for short-term therapy of tinea pedis. The use of ajoene as a 0.4% (w/w) cream resulted in complete clinical and mycological cure in 27 of 34 patients (79%) after 7 days of treatment. The remaining seven patients (21%) achieved complete cure after seven additional days of treatment. All patients were evaluated for recurrence of mycotic infections 90 days after the end of treatment, yielding negative cultures for fungus. These results identified ajoene as an alternative, efficient, and low-cost antimycotic drug for short-term therapy of tinea pedis.

Trial 2 (Ledezma et al., 2000 — Journal of the American Academy of Dermatology): This double-blind comparative study examined twice-daily topical application during 1 week of 0.6% and 1% ajoene and 1% terbinafine in the treatment of tinea pedis. Seventy soldiers from the Venezuelan Armed Forces with clinical and mycologic diagnosis of tinea pedis were included, though only 47 were available for final evaluation. Patients were randomly distributed into 3 treatment groups: 0.6% ajoene, 1% ajoene, and 1% terbinafine. Efficacy of the treatments, measured as mycologic cure 60 days after the end of therapy, was 72% for 0.6% ajoene, 100% for 1% ajoene, and 94% for 1% terbinafine.

A further trial by Ledezma et al. (1999, Arzneimittel-Forschung) evaluated ajoene in the topical short-term treatment of tinea cruris and tinea corporis in humans, in a randomized comparative study with terbinafine.

Evidence strength: The clinical antifungal evidence is promising but limited. The two principal trials were both small (fewer than 50 evaluable subjects each), conducted within a single research group, enrolled a specific military population, and used short follow-up periods. No large, multi-center, phase III randomized controlled trials have been published. The 1% ajoene cream showing 100% mycologic cure comparable to the standard antifungal terbinafine is notable but requires independent replication.

4.3 Anticancer Activity

Cancer-related research on ajoene spans in vitro studies, animal models, and a small human study involving topical application.

Leukemia — In vitro and ex vivo: Ajoene was shown to inhibit proliferation and induce apoptosis of several human leukemia CD34-negative cells including HL-60, U937, HEL, and OCIM-1. Ajoene also induces 30% apoptosis in myeloblasts from a chronic myeloid leukemia patient in blast crisis. More significantly, ajoene profoundly enhanced the apoptotic effect of the two chemotherapeutic drugs cytarabine and fludarabine in human CD34-positive resistant myeloid leukemia cells through enhancing their bcl-2 inhibitory and caspase-3 activation activities.

Quantitative ELISA measurement showed treatment of KG1-resistant leukemia cells with 40 µM ajoene alone to significantly reduce bcl-2 expression from 239.5 ± 1.5 in control cultures to only 22.0 ± 4.0 in ajoene-treated cultures.

Basal Cell Carcinoma — Human clinical observation: Topical application of ajoene was shown to be effective against patients with either nodular or superficial basal cell carcinoma (BCC). Ajoene-induced reduction in tumor size was seen in 17 out of 21 patients. This study was rather small, including 21 subjects with basal cell carcinoma. Topical application of ajoene on tumors for a period of six months resulted in significant reduction in tumor size in 17 out of 21 subjects.

In vivo (animal) tumor studies: Z-ajoene inhibited tumor growth by 38% and 42% in mice grafted with sarcoma 180 and hepatocarcinoma 22, respectively, representing the first demonstration of Z-ajoene as a potent inhibitor of tumor cell growth both in vitro and in vivo.

Evidence strength: The anticancer evidence for ajoene is largely preclinical (in vitro and murine models). The BCC human study involved only 21 subjects and lacked a randomized controlled design. The leukemia work, while mechanistically compelling, has been performed in cell lines and ex vivo patient samples, with no phase I/II clinical trials completed. More extensive clinical trials and toxicological evaluations are needed to validate the efficacy and safety of ajoene in human populations. The current state of evidence is preliminary and hypothesis-generating.

4.4 Antiparasitic Activity

Ajoene showed potent leishmanicidal activity in vitro against all Leishmania species studied. Concentrations higher than 0.3 µM led to total inhibition of growth, and 10 µM induced 100% lysis of Leishmania after 96 hours of incubation in a chemically defined culture medium. The 50% inhibitory concentration (IC50) for lysis was approximately 2 µM for all species.

The effect was dose-dependent, and a threefold increase in concentration (30 µM) produced 100% lysis of cultured forms after 72 hours. Ultrastructural studies showed a time- and dose-dependent morphological alteration of the mitochondria.

Evidence strength: All antiparasitic evidence for ajoene is confined to in vitro studies and animal models. No human clinical trials evaluating ajoene specifically for leishmaniasis or Chagas disease have been published.

4.5 Anti-inflammatory and Immunomodulatory Effects

Ajoene is a potent modulator of membrane-dependent functions of immune cells that are under control of the signal-transduction system. Many in vitro and in vivo studies have reported ajoene for its effective anti-inflammatory and immune-boosting properties.

Evidence strength: Anti-inflammatory effects have been documented in cell-based and animal studies; no human clinical trials have been conducted specifically to evaluate ajoene's anti-inflammatory activity as a primary endpoint.

4.6 Antibacterial Activity

Synthetic ajoene has been shown to perform as well as ajoene isolated from garlic in initial antibacterial testing. In vitro and in vivo studies have reported ajoene for its effective antimicrobial properties.

Evidence strength: Antibacterial data for ajoene are derived exclusively from in vitro studies. No clinical trials in humans have been published.

---

5. Body Systems and Health Areas Associated with Ajoene

• Cardiovascular / Hematological system: Inhibition of platelet aggregation and thrombus formation; inhibition of HMG-CoA reductase and cholesterol synthesis; inhibition of smooth muscle cell proliferation via protein prenylation pathways.
• Dermatology / Skin: Topical antifungal activity against dermatophytes (Trichophyton rubrum); topical use in basal cell carcinoma with preliminary human evidence of tumor size reduction.
• Oncology: Pro-apoptotic and antiproliferative effects in leukemia, solid tumor cell lines, and preliminary human data in BCC; potentiation of chemotherapy-induced apoptosis in drug-resistant cells.
• Infectious disease / Parasitology: In vitro leishmanicidal and trypanolytic activity; antifungal activity against dermatophytes and Candida species.
• Hepatic system: Ajoene inhibits thiol and glutathione (GSH) depletion from the liver and refurbishes liver enzymes in which toxicity is induced by acetaminophen (APAP).
• Immune system: Modulation of lymphocyte and macrophage membrane-dependent functions, with documented effects on signal transduction in immune cells.

---

6. Dosage Forms and Dosages Reported in Studies

All dosages reported here are drawn directly from the cited published studies. No standardized or approved therapeutic dose has been established for ajoene as of the current literature.

Topical Formulations (Human Studies)

• 0.4% (w/w) cream applied in the treatment of tinea pedis: complete clinical and mycological cure in 27 of 34 patients (79%) after 7 days of treatment.
• 0.6% and 1% concentrations, applied twice daily for 1 week, were evaluated in a double-blind comparison with 1% terbinafine.
• Topical application of ajoene on basal cell carcinoma tumors for a period of six months resulted in significant reduction in tumor size in 17 out of 21 subjects. The precise concentration of the BCC formulation was reported by Tilli et al. (2003) in Archives of Dermatological Research.

In Vitro Concentrations (Cell Studies)

• ID50 of 95 ± 5 µM for collagen-induced platelet aggregation in human platelet-rich plasma.
• 20 µM ajoene was used to demonstrate time-dependent activation of caspase-3-like activity and proteolytic processing of procaspase-3 and -8 in leukemia cells.
• 40 µM ajoene significantly reduced bcl-2 expression in KG1 resistant leukemia cells.
• 0.3 µM led to total inhibition of Leishmania growth; IC50 for lysis was approximately 2 µM for all Leishmania species studied.
• IC50 of 25 µM Z-ajoene for reversible inhibition of microtubule protein assembly in vitro.

---

7. Safety Considerations and Drug Interactions

Antiplatelet Activity and Bleeding Risk

Ajoene in garlic is recognized alongside omega-3 fatty acids in fish oil, ginger, ginkgo, and vitamin E as having antiplatelet properties, representing one of more than 120 dietary supplements that may interact with aspirin, clopidogrel, and dipyridamole. According to the Natural Medicines Comprehensive Database, approximately 180 dietary supplements have the potential to interact with warfarin, and more than 120 may interact with aspirin, clopidogrel, and dipyridamole.

Interactions with Anticoagulants

Because garlic is the main source of allicin and ajoene, it is important to note that this food has anticoagulant properties, and its consumption in conjunction with anticoagulant drugs such as warfarin can enhance their effect. The anticoagulant effect of garlic is enhanced by fish oil and vitamin E, so a patient's prior supplementation and/or medication should be taken into account before use of garlic extract.

Interactions with Antiretroviral Drugs

A study evaluated the metabolism of the antiretroviral drug saquinavir in HIV-positive patients after the consumption of garlic supplements, finding a 50% reduction in saquinavir bioavailability. The use of garlic or its active compounds can therefore reduce the effectiveness of antiretroviral treatment in HIV-positive patients.

Synergism with Antiplatelet Drugs

For collagen-induced platelet aggregation in human PRP, the ID50 for ajoene is 95 ± 5 µM. However, in the presence of antiaggregatory drugs such as prostacyclin, forskolin, indomethacin, and dipyridamole, the ID50 for ajoene decreases more than would be predicted on the basis of simple additive effects. Similarly, the ID50 for prostacyclin decreases from 1 nM to 0.15 nM in the presence of 80 µM ajoene. This pharmacodynamic synergism with standard antiplatelet drugs is a clinically relevant safety consideration.

Reversibility of Antiplatelet Effect

One pharmacologically important characteristic distinguishing ajoene from irreversible antiplatelet agents (such as aspirin) is that its inhibitory effect on platelet aggregation is reversible. In vitro, ajoene reversibly inhibits platelet aggregation as well as the release reaction induced by all known agonists.

Toxicological Data and Research Gaps

A number of issues about the bioactive chemicals in garlic that are affected by processing, as well as their possible toxicities, pharmacokinetics, and safety profile, need to be investigated in order to confirm garlic's health benefits for humans. Despite promising results, the underlying mechanisms of ajoene's bioactivity remain incompletely understood, particularly in the context of complex human pathologies. More extensive clinical trials and toxicological evaluations are required to validate the efficacy and safety of ajoene in human populations. No formal toxicology profile (LD50, maximum tolerated dose) for ajoene in humans has been published in the peer-reviewed literature accessible to date. Topical use in the published clinical trials was reported to be well-tolerated.

---

References

• ScienceDirect Topics — Ajoene Overview
• Ledezma E, Apitz-Castro R. "Ajoene, the main active compound of garlic (Allium sativum): a new antifungal agent." Rev Iberoam Micol. 2006;23(2):75–80. PubMed PMID 16854181
• Kaschula CH, Hunter R, Parker MI. "Garlic-derived anticancer agents: structure and biological activity of ajoene." Biofactors. 2010;36(1):78–85. PubMed PMID 20108330
• Kaschula CH et al. "Garlic-derived anticancer agents: structure and biological activity of ajoene." BioFactors (Wiley Online Library). 2010.
• Dirsch VM et al. "Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation." Mol Pharmacol. 2003. PubMed PMID 12642382
• American Chemical Society — Molecule of the Week: Ajoene
• Li M et al. "Antitumor activity of Z-ajoene, a natural compound purified from garlic: antimitotic and microtubule-interaction properties." Biochem Pharmacol. 2002. PubMed PMID 11960908
• Apitz-Castro R et al. "Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets." Thromb Res. 1986. PubMed PMID 3520940
• Dirsch VM et al. "Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation." PMC1573737
• Apitz-Castro R et al. "Ajoene inhibition of platelet aggregation: possible mediation by a hemoprotein." PubMed PMID 3132169
• Apitz-Castro R et al. "Evidence for direct coupling of primary agonist-receptor interaction to the exposure of functional IIb-IIIa complexes in human blood platelets. Results from studies with the antiplatelet compound ajoene." Biochim Biophys Acta. 1991. PubMed PMID 1911878
• Apitz-Castro R, Badimon JJ, Badimon L. "Effect of ajoene, the major antiplatelet compound from garlic, on platelet thrombus formation." Thromb Res. 1992. PubMed PMID 1475777
• Apitz-Castro R et al. "Ajoene, the antiplatelet compound derived from garlic, specifically inhibits platelet release reaction by affecting the plasma membrane internal microviscosity." Thromb Haemost. 1989. PubMed PMID 2539823
• Ledezma E et al. "Efficacy of ajoene, an organosulphur derived from garlic, in the short-term therapy of tinea pedis." Mycoses. 1996;39:393–395. PubMed PMID 9009665
• Ledezma E et al. "Efficacy of ajoene in the treatment of tinea pedis: a double-blind and comparative study with terbinafine." J Am Acad Dermatol. 2000;43:829–32. PubMed PMID 11050588
• Ledezma E et al. "Efficacy of ajoene in the treatment of tinea pedis: A double-blind and comparative study with terbinafine." Journal of the American Academy of Dermatology. 2000. ScienceDirect.
• Hassan HT. "Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy." Leuk Res. 2004;28(7):667–71. PubMed PMID 15158086
• Dirsch VM et al. "Ajoene, an experimental anti-leukemic drug: mechanism of cell death." Leukemia. 2002;16(1):74–83. PubMed PMID 11840266
• Dirsch VM et al. "Ajoene, an experimental anti-leukemic drug: mechanism of cell death." Leukemia. Nature Publishing. 2002.
• Ahmed N et al. "Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells." Anticancer Res. 2001;21(5):3519–23. PubMed PMID 11848518
• Ledezma E et al. "Antiproliferative and leishmanicidal effect of ajoene on various Leishmania species: ultrastructural study." Parasitology Research. 2002. Springer.
• Bayan L et al. "Garlic: a review of potential therapeutic effects." Avicenna J Phytomed. 2014. PMC4103721
• Frontiers in Immunology — "Garlic bioactive substances and their therapeutic applications for improving human health: a comprehensive review." PMC11194342. 2024.
• Heber D et al. "Antithrombotic effects of naturally derived products on coagulation and platelet function." Methods Mol Biol. 2010. PubMed PMID 20617421
• Petrovska BB, Cekovska S. "Extracts from the history and medical properties of garlic." Pharmacogn Rev. 2010. PMC3249897
• PMC6093621 — "Next-Gen therapeutics for Skin Cancer: Nutraceuticals." PMC article including Tilli et al. 2003 BCC data.
• US Patent 8623923 — "Process for the preparation of ajoene." USPTO.
• Wikipedia — Ajoene